Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer

Inclusion Criteria

• •Patients must have a cytological or histological diagnosis of adenocarcinoma arising in the pancreas. Diagnosis from metastatic sampling is acceptable.
• •Disease must be measured radiologically.
• •Failed initial therapy or ineligible for definitive curative therapy.
• •If prior treatment included radiation therapy, recurrent disease must be outside of the targeted volume.
• •Age ≥ 18 years
• •ECOG performance status 0-2 (Karnofsky \> 50%, see Appendix A).
• •Patients must have normal organ and marrow function as defined below:
• •* leukocytes ≥ 3,000/mm3
• •* absolute neutrophil count ≥ 1,500/mm3
• •* platelets ≥ 100,000/mm3
• •* total bilirubin \< 2x institutional upper limit of normal
• •* AST(SGOT) \< 3x institutional upper limit of normal OR \< 5x institutional upper limit of normal for patients presenting with liver metastases
• •* ALT (SGPT) \< 3x institutional upper limit of normal OR \< 5x institutional upper limit of normal for patients presenting with liver metastases
• •* PT/INR within normal institutional limits, unless patient is on warfarin or other antithrombotic agents
• •* creatinine \< 1.5 X institutional upper limit of normal OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
• •* Not pregnant. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• •* Ability to understand and the willingness to sign a written informed consent document.